⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL856297 | 0.96 | — | — | |
| SCHEMBL23209159 | 0.83 | — | — | |
| SCHEMBL803572 | 0.78 | — | — | |
| SCHEMBL3395618 | 0.75 | — | — | |
| SCHEMBL22728570 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL184285 | 0.75 | — | — | |
| SCHEMBL3072169 | 0.75 | — | — | |
| SCHEMBL28085887 | 0.73 | — | — | |
| SCHEMBL20985101 | 0.72 | ALDH1A1 (0.39) | — | |
| Hydrochloric Acid SCHEMBL17476096 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12616696-B2 | Crystalline forms of (p)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2′-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5′,6-dimethyl-2h-[1,4′-bipyridin]-2-one | ACLARIS THERAPEUTICS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12545662-B2 | MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| CN-119454711-A | Methods, compositions and crystalline forms of substituted pyridone-pyridinyl compounds | 阿克拉瑞斯治疗股份有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119431374-A | Pyridine-containing polycyclic derivative, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-119053588-A | P38 alpha-MK 2 inhibitor compound, pharmaceutical composition and application thereof | 长春金赛药业有限责任公司 | 2024-11-29 | — | — | CN | disclosed |
| CN-115484952-B | Methods, compositions and crystalline forms of substituted pyridone-pyridinyl compounds | 阿克拉瑞斯治疗股份有限公司 | 2024-10-18 | — | — | CN | disclosed |
| US-20240239778-A1 | GRISEOFULVIN COMPOUND AND PHARMACEUTICAL USE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-07-18 | — | — | US | disclosed |
| US-11993593-B2 | Griseofulvin compound and pharmaceutical use thereof | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-05-28 | — | — | US | disclosed |
| US-11987574-B2 | MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| WO-2024046327-A1 | P38α-MK2 INHIBITOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF | 长春金赛药业有限责任公司 | 2024-03-07 | — | — | WO | disclosed |
| WO-2008097428-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008081207-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008081206-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008081208-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008081204-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008081205-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008074803-A2 | 4-BENZYL-L ( 2H) -PHTHALAZINONES AS H1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| EP-1765795-A2 | ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharmaceuticals SA (CH) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005123703-A2 | ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2005-12-29 | — | — | WO | disclosed |
| US-3965176-A | ANTIANDROGENIC | SCHERING CORPORATION (US) | 1976-06-22 | — | — | US | disclosed |